T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches

Ramos, Ana Colon; Tarekegn, Kidist; Aujla, Amandeep; Jesus, Katherine de de Garcia; Gupta, Sachin

doi:10.7759/cureus.13237

Cited by 6 publications

(3 citation statements)

References 34 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…JAK inhibitors (tofacitinib/ruxolitinib) and selective STAT-5 inhibitors like pimozide have proven effective in case reports and are being further studied in clinical trials. [21][22][23] Chimeric antigen receptor (CAR) T-cell therapy is an emerging field that has potential applications in T-cell malignancies. CD30 may be a possible target antigen.…”

Section: Discussionmentioning

confidence: 99%

Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion

Wasifuddin

Sabzposh

Sun

et al. 2023

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm that originates from mature post-thymic T-cells. Cutaneous manifestations are a common presentation in T-PLL but rarely are a presentation in the recurrent setting. Here, we describe the case of a 75-year-old female with a history of T-PLL—who at the time of initial diagnosis did not exhibit any rash—presenting with diffuse rash, facial swelling, sore throat, and dysphagia 7 months later and was found to have recurrent T-PLL. She had diffuse lymphadenopathy and diffuse skin lesions. Biopsy of the skin lesions also confirmed infiltration with T-PLL cells. After review of the literature, no previously reported cases of recurrent T-PLL presented as diffuse skin lesions. This case demonstrates that recurrent T-PLL may present with diffuse rash, respiratory distress, and anasarca. It is important to stay vigilant in patients with history of T-PLL to recognize signs of recurrent disease to allow prompt diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion

Wasifuddin

Sabzposh

Sun

et al. 2023

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

show abstract

“…The most common translocation in this group is t(X;14)(q28;q11.2). In the majority of cases, additional abnormalities are observed, which include i(8)(q10) or other rearrangements leading to gain of 8q, deletion or rearrangements of 11q, and deletions of 6q, 12p, and 17p [129][130][131].…”

Section: T-cell Prolymphocytic Leukemia (T-pll)mentioning

confidence: 99%

Chromosome Abnormalities in Hematological Malignancies and Its Clinical Significance

Subramanian¹

2022

Down Syndrome and Other Chromosome Abnormalities

View full text Add to dashboard Cite

The latest version of the World Health Organization guidelines focuses mainly on the genetic and cytogenetic features of hematologic neoplasms as predictors of diagnostic, treatment decision, prognostic outcome, and for treatment monitoring in hematological malignancies. There are different techniques to identify these abnormalities. Live cells are needed for chromosome preparation. The Hematological malignancies include myeloid and lymphoid neoplasms. The myeloid neoplasms include Myelodysplastic syndromes, myeloproliferative neoplasms, and acute myeloid leukemias. The Lymphoid neoplasms include acute and chronic lymphocytic leukemias, plasma cell neoplasms, myeloma, hodgkin, and non-hodgkin lymphomas. The first chromosomal abnormality discovered in connection with cancer is the Philadelphia chromosome, which is an abnormal chromosome 22, formed due to the translocation between chromosomes 9 and 22. The presence of this abnormal chromosome confirms the diagnosis of “CML”. After that, hundreds of chromosomal abnormalities have been identified in hematological malignancies in different parts of the world. In AML, specific abnormalities were identified as having a good prognosis, intermediate prognosis, and poor prognosis. In other hematological malignancies also there some specific chromosome abnormalities are associated with prognostication. Now a day’s clinicians depend mainly on genetic abnormalities for the proper treatment management of hematological malignancies, so the study of chromosomal abnormalities is essential.

show abstract

“…T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive type of hematological malignancy characterized by the abnormal proliferation of mature T lymphocytes in the blood, bone marrow, and various organs [ 1 ]. The treatment options for T-PLL are limited, and alemtuzumab remains the first-line therapy for treatment-naive and relapsed/refractory patients [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Disseminated Cryptococcosis With Prostate Involvement in a Patient With T-cell Prolymphocytic Leukemia and Prostate Cancer

Ioannidis,

Mavridis,

Anagnostakis

et al. 2024

Cureus

View full text Add to dashboard Cite

T-cell prolymphocytic leukemia (T-PLL) presents unique treatment challenges because of its rarity and aggressiveness. Allogeneic hematopoietic stem cell transplantation offers a potentially curative option, but its safety in patients with concurrent invasive fungal infections and solid malignancies remains uncertain. We present a case of a 68-year-old male with T-PLL who developed disseminated cryptococcal disease with prostate involvement and concurrent prostate cancer (PCa). Despite the challenges, successful control of the infection and radical prostatectomy enabled the patient to proceed safely to allogeneic transplantation. The case highlights the importance of vigilance for unusual infections, such as Cryptococcus, in immunocompromised patients presenting with lower urinary tract symptoms. Clinicians should consider the possibility of PCa in this population, particularly in the context of chronic leukemia. Concurrently, the potential association between fungal prostate infections and PCa warrants further investigation.

show abstract

T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches

Cited by 6 publications

References 34 publications

Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion

Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion

Chromosome Abnormalities in Hematological Malignancies and Its Clinical Significance

Disseminated Cryptococcosis With Prostate Involvement in a Patient With T-cell Prolymphocytic Leukemia and Prostate Cancer

Contact Info

Product

Resources

About